https://www.selleckchem.com/pr....oducts/DMXAA(ASA404)
Changes in serotype distribution have been described after the switch from the 13-valent pneumococcal conjugate vaccine (PCV13) to the 10-valent pneumococcal conjugate vaccine (PCV1 in Belgium. To describe serotype's invasive disease potential and the detailed evolution of serotype distribution and antimicrobial susceptibility of pneumococcal isolates (carriage and IPD) in children up to 30months of age over a period during and after the vaccine switch (2015-2018). S. pneumoniae strains isolated from the nasopharynx of healthy c